Pharmaceuticals US

US Severe Asthma Biologics Market Analysis, 2024–2034

US Severe Asthma Biologics Market Industry Trends and Forecast to 2034: Segmented by (Target, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $5.95 Bn Estimated value
Estimate 2025 $6.44 Bn 44.3% of the global market
Projected 2034 $12.98 Bn 101.6% Adds $6.54 Bn over 9 forecast years
CAGR 2025–2034 8.1% Faster than 62% of 180 Pharmaceuticals markets here
Key players 5
  • US is 44.33% of the global market.
  • In North America, the largest is US (this report) at $6.44 Bn.
  • Fastest growing: Canada at 9.7% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$6.54 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Severe Asthma Biologics Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $5.95 Bn — —
2025 (base) $6.44 Bn +$482.3 Mn —
2026 (forecast) $6.96 Bn +$521.4 Mn +8.1%
2027 (forecast) $7.52 Bn +$563.7 Mn +16.9%
2028 (forecast) $8.13 Bn +$609.3 Mn +26.3%
2029 (forecast) $8.79 Bn +$658.7 Mn +36.6%
2030 (forecast) $9.50 Bn +$712.0 Mn +47.6%
2031 (forecast) $10.27 Bn +$769.7 Mn +59.6%
2032 (forecast) $11.10 Bn +$832.0 Mn +72.5%
2033 (forecast) $12.00 Bn +$899.4 Mn +86.5%
2034 (forecast) $12.98 Bn +$972.3 Mn +101.6%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $14.52 Bn
  2. North America $7.19 Bn
  3. US (this report) $6.44 Bn
  4. APAC $3.19 Bn
  5. Europe $2.30 Bn
  6. China $1.33 Bn
  7. Canada $1.08 Bn
  8. Japan $984.4 Mn
  9. Latin America $730.5 Mn
  10. Middle East $625.1 Mn
  11. Germany $483.4 Mn
  12. Italy $385.4 Mn
  13. Brazil $381.6 Mn
  14. France $358.6 Mn
  15. UK $329.5 Mn
  16. Saudi Arabia $289.8 Mn
  17. India $280.3 Mn
  18. Ecuador $252.9 Mn
  19. Mexico $246.6 Mn
  20. Spain $240.6 Mn
  21. Africa $212.4 Mn
  22. Australia $190.1 Mn
  23. New Zealand $167.0 Mn
  24. Russia $134.9 Mn
  25. South Africa $103.4 Mn
  26. UAE $76.9 Mn
  27. Egypt $44.9 Mn
  28. Philippines $33.5 Mn
  29. Hong Kong $26.6 Mn
  30. Malaysia $22.3 Mn
  31. Thailand $19.9 Mn
  32. Singapore $16.3 Mn
  33. Kenya $11.5 Mn

The US Severe Asthma Biologics Market Analysis Executive Summary

Severe asthma biologics are injections that block immune signals driving severe asthma attacks.

Key segments of the severe Asthma Biologics market include target (IL-5, IL-4/IL-13 and IgE) and age (Children and Adults).

US Severe Asthma Biologics Market Dynamics

Market Growth Drivers

Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the severe Asthma Biologics market.

Opportunity

Earlier screening, new drug classes and home-based care give the severe Asthma Biologics market room to grow.

Market Restraints

Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the severe Asthma Biologics market.

Competitive Landscape for Severe Asthma Biologics Market in US

The severe Asthma Biologics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Severe Asthma Biologics Market in US

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for severe Asthma Biologics. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Severe Asthma Biologics right now, from free public sources.

Clinical trials

37 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. AstraZeneca 15 active trials on ClinicalTrials.gov (opens in a new tab)
  2. Pfizer Inc. 3 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Shanghai Mabgeek Biotech.Co.Ltd 2 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Generate Biomedicines 2 active trials on ClinicalTrials.gov (opens in a new tab)
  5. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 322 papers since 2021 (worldwide)

  1. Is It Safe to Reduce Inhaled Corticosteroid Dose in Severe Asthma Patients Receiving Biologic Therapy? Clinical and translational allergy, 2026
  2. Tracking severe asthma improvement with biologic therapy using spirometry and impulse oscillometry: a real-world study. Multidisciplinary respiratory medicine, 2026
  3. Inhaled corticosteroid adherence in the era of biologics for severe asthma. ERJ open research, 2026
  4. Therapeutic Switching of Biological Drugs in Paediatric Severe Asthma: Experience of a Referral Centre. Biomedicines, 2026
  5. Clinical Remission Trajectories Beyond 12 Months in Severe Asthma Patients Continuing a Single Biologic: A Real-World Single SANI Center Cohort. Medical sciences (Basel, Switzerland), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Severe Asthma Biologics in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

Questions, answered with public data

How many clinical trials on Severe Asthma Biologics are running in the US?
37 studies are recruiting, active or about to start in the US.[4]
How much research is published on Severe Asthma Biologics?
PubMed lists 322 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Severe Asthma Biologics in US? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Airway Management Devices: Critical Tools in EmergenciesKeeping the airway open is the first step in saving a life. More than half of deaths in low- and… Anaesthesia and Respiratory Devices: Lessons After COVIDMore than 5 billion people lack access to safe, affordable medical oxygen. COVID-19 exposed gaps in…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in US

See all
Same topic, other categories

Related on respiratory and biologics and biosimilars

See the topic